Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*

Abstract

In this 18-week study, the addition of sitagliptin was effective and well tolerated in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Treatment with sitagliptin produced similar reductions in HbA(1c) compared with the addition of rosiglitazone.